The addition of a MEK inhibitor to a BRAF inhibitor (PLX4720) enhanced tumor regression and prolonged survival in ATC-bearing mice [87] Moreover, a combination therapy of BRAFV600E inhibitor (PLX4720) and anti-PD-L1/PD-1 antibody reduced tumor volume and improved survival of an immunocompetent mouse model of orthotopic ATC [88]. Here, PDCD1 is linked to neoplasm.